Literature DB >> 27601656

In B cells, phosphatidylinositol 5-phosphate 4-kinase-α synthesizes PI(4,5)P2 to impact mTORC2 and Akt signaling.

Simon J Bulley1, Alaa Droubi1, Jonathan H Clarke1, Karen E Anderson2, Len R Stephens2, Phillip T Hawkins2, Robin F Irvine3.   

Abstract

Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are enigmatic lipid kinases with physiological functions that are incompletely understood, not the least because genetic deletion and cell transfection have led to contradictory data. Here, we used the genetic tractability of DT40 cells to create cell lines in which endogenous PI5P4Kα was removed, either stably by genetic deletion or transiently (within 1 h) by tagging the endogenous protein genomically with the auxin degron. In both cases, removal impacted Akt phosphorylation, and by leaving one PI5P4Kα allele present but mutating it to be kinase-dead or have PI4P 5-kinase activity, we show that all of the effects on Akt phosphorylation were dependent on the ability of PI5P4Kα to synthesize phosphatidylinositol (4,5)-bisphosphate [PI(4,5)P2] rather than to remove PI5P. Although stable removal of PI5P4Kα resulted in a pronounced decrease in Akt phosphorylation at Thr308 and Ser473, in part because of reduced plasma membrane PIP3, its acute removal led to an increase in Akt phosphorylation only at Ser473. This process invokes activation primarily of mammalian target of rapamycin complex 2 (mTORC2), which was confirmed by increased phosphorylation of other mTORC2 substrates. These findings establish PI5P4Kα as a kinase that synthesizes a physiologically relevant pool of PI(4,5)P2 and as a regulator of mTORC2, and show a phenomenon similar to the "butterfly effect" described for phosphatidylinositol 3-kinase Iα [Hart JR, et al. (2015) Proc Natl Acad Sci USA 112(4):1131-1136], whereby through apparently the same underlying mechanism, the removal of a protein's activity from a cell can have widely divergent effects depending on the time course of that removal.

Entities:  

Keywords:  Akt; mTOR; phosphatidylinositol (4,5)-bisphosphate; phosphatidylinositol 5-phosphate; phosphatidylinositol 5-phosphate 4-kinase

Mesh:

Substances:

Year:  2016        PMID: 27601656      PMCID: PMC5035885          DOI: 10.1073/pnas.1522478113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  The B cell antigen receptor activates the Akt (protein kinase B)/glycogen synthase kinase-3 signaling pathway via phosphatidylinositol 3-kinase.

Authors:  M R Gold; M P Scheid; L Santos; M Dang-Lawson; R A Roth; L Matsuuchi; V Duronio; D L Krebs
Journal:  J Immunol       Date:  1999-08-15       Impact factor: 5.422

2.  Stereo-specific substrate recognition by phosphatidylinositol phosphate kinases is swapped by changing a single amino acid residue.

Authors:  Jeannette Kunz; Allison Fuelling; Lottie Kolbe; Richard A Anderson
Journal:  J Biol Chem       Date:  2001-11-30       Impact factor: 5.157

3.  PIP4Kbeta interacts with and modulates nuclear localization of the high-activity PtdIns5P-4-kinase isoform PIP4Kalpha.

Authors:  Yvette Bultsma; Willem-Jan Keune; Nullin Divecha
Journal:  Biochem J       Date:  2010-09-01       Impact factor: 3.857

4.  PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.

Authors:  Pengda Liu; Wenjian Gan; Y Rebecca Chin; Kohei Ogura; Jianping Guo; Jinfang Zhang; Bin Wang; John Blenis; Lewis C Cantley; Alex Toker; Bing Su; Wenyi Wei
Journal:  Cancer Discov       Date:  2015-08-20       Impact factor: 39.397

5.  The butterfly effect in cancer: a single base mutation can remodel the cell.

Authors:  Jonathan R Hart; Yaoyang Zhang; Lujian Liao; Lynn Ueno; Lisa Du; Marloes Jonkers; John R Yates; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-12       Impact factor: 11.205

6.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.

Authors:  Tianyan Gao; Frank Furnari; Alexandra C Newton
Journal:  Mol Cell       Date:  2005-04-01       Impact factor: 17.970

7.  Increased insulin sensitivity and reduced adiposity in phosphatidylinositol 5-phosphate 4-kinase beta-/- mice.

Authors:  Katja A Lamia; Odile D Peroni; Young-Bum Kim; Lucia E Rameh; Barbara B Kahn; Lewis C Cantley
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

8.  Protein kinase CK2 impairs spatial memory formation through differential cross talk with PI-3 kinase signaling: activation of Akt and inactivation of SGK1.

Authors:  Chih C Chao; Yun L Ma; Eminy H Y Lee
Journal:  J Neurosci       Date:  2007-06-06       Impact factor: 6.167

9.  Protein kinase C mediates translocation of type II phosphatidylinositol 5-phosphate 4-kinase required for platelet alpha-granule secretion.

Authors:  Nataliya Rozenvayn; Robert Flaumenhaft
Journal:  J Biol Chem       Date:  2002-12-30       Impact factor: 5.157

10.  Genomic tagging of endogenous type IIbeta phosphatidylinositol 5-phosphate 4-kinase in DT40 cells reveals a nuclear localisation.

Authors:  Jonathan P Richardson; Minchuan Wang; Jonathan H Clarke; Ketan J Patel; R F Irvine
Journal:  Cell Signal       Date:  2007-01-20       Impact factor: 4.315

View more
  7 in total

1.  Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.

Authors:  Sindhu Carmen Sivakumaren; Hyeseok Shim; Tinghu Zhang; Fleur M Ferguson; Mark R Lundquist; Christopher M Browne; Hyuk-Soo Seo; Marcia N Paddock; Theresa D Manz; Baishan Jiang; Ming-Feng Hao; Pranav Krishnan; Diana G Wang; T Jonathan Yang; Nicholas P Kwiatkowski; Scott B Ficarro; James M Cunningham; Jarrod A Marto; Sirano Dhe-Paganon; Lewis C Cantley; Nathanael S Gray
Journal:  Cell Chem Biol       Date:  2020-03-03       Impact factor: 8.116

2.  Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors.

Authors:  Theresa D Manz; Sindhu C Sivakumaren; Adam Yasgar; Matthew D Hall; Mindy I Davis; Hyuk-Soo Seo; Joseph D Card; Scott B Ficarro; Hyeseok Shim; Jarrod A Marto; Sirano Dhe-Paganon; Atsuo T Sasaki; Matthew B Boxer; Anton Simeonov; Lewis C Cantley; Min Shen; Tinghu Zhang; Fleur M Ferguson; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2019-11-03       Impact factor: 4.345

3.  Discovery and Structure-Activity Relationship Study of (Z)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors.

Authors:  Theresa D Manz; Sindhu Carmen Sivakumaren; Fleur M Ferguson; Tinghu Zhang; Adam Yasgar; Hyuk-Soo Seo; Scott B Ficarro; Joseph D Card; Hyeseok Shim; Chandrasekhar V Miduturu; Anton Simeonov; Min Shen; Jarrod A Marto; Sirano Dhe-Paganon; Matthew D Hall; Lewis C Cantley; Nathanael S Gray
Journal:  J Med Chem       Date:  2020-04-27       Impact factor: 7.446

Review 4.  Phosphoinositide 3-kinase pathways and autophagy require phosphatidylinositol phosphate kinases.

Authors:  Suyong Choi; Xander Houdek; Richard A Anderson
Journal:  Adv Biol Regul       Date:  2018-02-08

5.  Pharmacological inhibition of PI5P4Kα/β disrupts cell energy metabolism and selectively kills p53-null tumor cells.

Authors:  Song Chen; Caroline Chandra Tjin; Xiang Gao; Yi Xue; Haoyan Jiao; Ruilin Zhang; Mengnan Wu; Zunyu He; Jonathan Ellman; Ya Ha
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-25       Impact factor: 11.205

6.  Phosphatidylinositol 5 Phosphate 4-Kinase Regulates Plasma-Membrane PIP3 Turnover and Insulin Signaling.

Authors:  Sanjeev Sharma; Swarna Mathre; Visvanathan Ramya; Dhananjay Shinde; Padinjat Raghu
Journal:  Cell Rep       Date:  2019-05-14       Impact factor: 9.423

7.  Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode.

Authors:  Helen K Boffey; Timothy P C Rooney; Henriette M G Willems; Simon Edwards; Christopher Green; Tina Howard; Derek Ogg; Tamara Romero; Duncan E Scott; David Winpenny; James Duce; John Skidmore; Jonathan H Clarke; Stephen P Andrews
Journal:  J Med Chem       Date:  2022-02-11       Impact factor: 8.039

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.